Patent classifications
C07K14/4736
Peptide for treating cancer
A peptide is disclosed that has an amino acid sequence selected from X.sub.1-X.sub.2-X.sub.3-Gln-Leu-Met-Leu-Cys-Val-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 3), X.sub.1-X.sub.2-X.sub.3-Gln-X.sub.7-Met-X.sub.10-Cys-Val-X.sub.11-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 4), Ile-Ser-Phe-Gln-Leu-Met-Leu (SEQ ID NO: 5), Leu-Cys-Val-Leu-Asp-Tyr-Phe (SEQ ID NO: 6), X.sub.1-X.sub.2-X.sub.3-Gln-Leu-X.sub.8-Leu-X.sub.9-Val-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 7), X.sub.1-X.sub.2-X.sub.3-Gln-Leu-X.sub.8-Leu-X.sub.9-Val-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 7), X.sub.1-X.sub.2-X.sub.3-X.sub.12-Leu-Met-Leu-Cys-X.sub.13-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 10), Gln-X.sub.7-Met-X.sub.10-Cys-Val-X.sub.11 (SEQ ID NO: 11), Gln-Leu-X.sub.8-Leu-X.sub.9-Val-Leu (SEQ ID NO: 12), X.sub.12-Leu-Met-Leu-Cys-X.sub.13-Leu (SEQ ID NO: 13), Asp-Leu-Val-Ile-Ser-Phe-Gln-Leu-Met-Leu-Cys-Val-Leu-Asp-Tyr-Phe-Ile-Lys (SEQ ID NO: 14) and retro-inverso peptides thereof. The peptides disclosed herein may be used to treat liver cancer, lung cancer, breast cancer, pancreatic cancer, or brain cancer.
CYCLIC PEPTIDE FOR TREATING CANCER
The present disclosure generally relates to a circularized peptide for treating cancer. An cyclic peptide is disclosed that has an amino acid sequence selected from Lys-X.sub.5-Glu-X.sub.1-X.sub.2-Gln-Met-Glu-Asp-Asp-X.sub.3-X.sub.4 (SEQ ID NO: 3), X.sub.10-Gly-Glu-Val-Leu-X.sub.11-Met-Glu-Asp-Asp-Leu-Val (SEQ ID NO: 4), Lys-Gly-X.sub.6-Val-Leu-Gln-Met-X.sub.7-X.sub.8-X.sub.9-Leu-Val (SEQ ID NO: 5), Lys-X.sub.5-Glu-X.sub.1-X.sub.2-Gln-X.sub.12-Glu-Asp-Asp-X.sub.3-X.sub.4 (SEQ ID NO: 9), and X.sub.10-X.sub.5-X.sub.6-Val-Leu-Gln-Met-Glu-Asp-X.sub.9-X.sub.3-X.sub.4 (SEQ ID NO: 10). The amino acids X.sub.1, X.sub.2, X.sub.3, and X.sub.4 can be each independently valine, leucine, isoleucine, or alanine; X.sub.5 can be glycine, alanine, leucine, isoleucine, or valine; X.sub.6, X.sub.7, X.sub.8, and X.sub.9 can be each independently glutamic acid or asparagine; X.sub.10 can be lysine or arginine; X.sub.11 can be methionine or cysteine; and X.sub.12 can be methionine or norleucine. The cyclic peptide can have the amino acid sequence Lys-Gly-Glu-Val-Leu-Gln-Met-Glu-Asp-Asp-Leu-Val (SEQ ID NO: 1).
TARGETED AUGMENTATION OF NUCLEAR GENE OUTPUT
Provided herein are methods and compositions for increasing production of a target protein or functional RNA by a cell.
PEPTIDE FOR TREATING CANCER
A peptide is disclosed that has an amino acid sequence selected from X.sub.1-X.sub.2-X.sub.3-Gln-Leu-Met-Leu-Cys-Val-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 3), X.sub.1-X.sub.2-X.sub.3-Gln-X.sub.7-Met-X.sub.10 -Cys-Val-X.sub.11-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 4), Ile-Ser-Phe-Gln-Leu-Met-Leu (SEQ ID NO: 5), Leu-Cys-Val-Leu-Asp-Tyr-Phe (SEQ ID NO: 6), X.sub.1-X.sub.2-X.sub.3-Gln-Leu-X.sub.8-Leu-X.sub.9-Val-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 7), X.sub.1-X.sub.2-X.sub.3-Gln-Leu-X.sub.8-Leu-X.sub.9-Val-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 7), X.sub.1-X.sub.2-X.sub.3-X.sub.12-Leu-Met-Leu-Cys-X.sub.13-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 10), Gln-X.sub.7-Met-X.sub.10-Cys-Val-X.sub.11 (SEQ ID NO: 11), Gln-Leu-X.sub.8-Leu-X.sub.9-Val-Leu (SEQ ID NO: 12), X.sub.12-Leu-Met-Leu-Cys-X.sub.13-Leu (SEQ ID NO: 13), Asp-Leu-Val-Ile-Ser-Phe-Gln-Leu-Met-Leu-Cys-Val-Leu-Asp-Tyr-Phe-Ile-Lys (SEQ ID NO: 14) and retro-inverso peptides thereof. The peptides disclosed herein may be used to treat liver cancer, lung cancer, breast cancer, pancreatic cancer, or brain cancer.
Cyclic peptide for treating cancer
The present disclosure generally relates to a circularized peptide for treating cancer. An cyclic peptide is disclosed that has an amino acid sequence selected from Lys-X.sub.5-Glu-X.sub.1-X.sub.2-Gln-Met-Glu-Asp-Asp-X.sub.3-X.sub.4 (SEQ ID NO: 3), (SEQ ID NO: 4), Lys-Gly-X.sub.6-Val-Leu-Gln-Met-X.sub.7-X.sub.8-X.sub.9-Leu-Val (SEQ ID NO: 5), Lys-X.sub.5-Glu-X.sub.1-X.sub.2-Gln-X.sub.12-Glu-Asp-Asp-X.sub.3-X.sub.4 (SEQ ID NO: 9), and X.sub.10-X.sub.5-X.sub.6-Val-Leu-Gln-Met-Glu-Asp-X.sub.9-X.sub.3-X.sub.4 (SEQ ID NO: 10). The amino acids X.sub.1, X.sub.2, X.sub.3, and X.sub.4 can be each independently valine, leucine, isoleucine, or alanine; X.sub.5 can be glycine, alanine, leucine, isoleucine, or valine; X.sub.6, X.sub.7, X.sub.8, and X.sub.9 can be each independently glutamic acid or asparagine; X.sub.10 can be lysine or arginine; X.sub.11 can be methionine or cysteine; and X.sub.12 can be methionine or norleucine. The cyclic peptide can have the amino acid sequence Lys-Gly-Glu-Val-Leu-Gln-Met-Glu-Asp-Asp-Leu-Val (SEQ ID NO: 1).
Targeted augmentation of nuclear gene output
Provided herein are methods and compositions for increasing production of a target protein or functional RNA by a cell.
CYCLIC PEPTIDE FOR TREATING CANCER
The present disclosure generally relates to a circularized peptide for treating cancer. An cyclic peptide is disclosed that has an amino acid sequence selected from Lys-X.sub.5-Glu-X.sub.1-X.sub.2-Gln-Met-Glu-Asp-Asp-X.sub.3-X.sub.4 (SEQ ID NO: 3), (SEQ ID NO: 4), Lys-Gly-X.sub.6-Val-Leu-Gln-Met-X.sub.7-X.sub.8-X.sub.9-Leu-Val (SEQ ID NO: 5), Lys-X.sub.5-Glu-X.sub.1-X.sub.2-Gln-X.sub.12-Glu-Asp-Asp-X.sub.3-X.sub.4 (SEQ ID NO: 9), and X.sub.10-X.sub.5-X.sub.6-Val-Leu-Gln-Met-Glu-Asp-X.sub.9-X.sub.3-X.sub.4 (SEQ ID NO: 10). The amino acids X.sub.1, X.sub.2, X.sub.3, and X.sub.4 can be each independently valine, leucine, isoleucine, or alanine; X.sub.5 can be glycine, alanine, leucine, isoleucine, or valine; X.sub.6, X.sub.7, X.sub.8, and X.sub.9 can be each independently glutamic acid or asparagine; X.sub.10 can be lysine or arginine; X.sub.11 can be methionine or cysteine; and X.sub.12 can be methionine or norleucine. The cyclic peptide can have the amino acid sequence Lys-Gly-Glu-Val-Leu-Gln-Met-Glu-Asp-Asp-Leu-Val (SEQ ID NO: 1).
TARGETED AUGMENTATION OF NUCLEAR GENE OUTPUT
Provided herein are methods and compositions for increasing production of a target protein or functional RNA by a cell.
Targeted augmentation of nuclear gene output
Provided herein are methods and compositions for increasing production of a target protein or functional RNA by a cell.
Cyclic peptide for treating cancer
The present disclosure generally relates to a circularized peptide for treating cancer. An cyclic peptide is disclosed that has an amino acid sequence selected from Lys-X.sub.5-Glu-X.sub.1-X.sub.2-Gln-Met-Glu-Asp-Asp-X.sub.3-X.sub.4 (SEQ ID NO: 3), X.sub.10-Gly-Glu-Val-Leu-X.sub.11-Met-Glu-Asp-Asp-Leu-Val (SEQ ID NO: 4), Lys-Gly-X.sub.6-Val-Leu-Gln-Met-X.sub.7-X.sub.8-X.sub.9-Leu-Val (SEQ ID NO: 5), Lys-X.sub.5-Glu-X.sub.1-X.sub.2-Gln-X.sub.12-Glu-Asp-Asp-X.sub.3-X.sub.4 (SEQ ID NO: 9), and X.sub.10-X.sub.5-X.sub.6-Val-Leu-Gln-Met-Glu-Asp-X.sub.9-X.sub.3-X.sub.4 (SEQ ID NO: 10). The amino acids X.sub.1, X.sub.2, X.sub.3, and X.sub.4 can be each independently valine, leucine, isoleucine, or alanine; X.sub.5 can be glycine, alanine, leucine, isoleucine, or valine; X.sub.6, X.sub.7, X.sub.8, and X.sub.9 can be each independently glutamic acid or asparagine; X.sub.10 can be lysine or arginine; X.sub.11 can be methionine or cysteine; and X.sub.12 can be methionine or norleucine. The cyclic peptide can have the amino acid sequence Lys-Gly-Glu-Val-Leu-Gln-Met-Glu-Asp-Asp-Leu-Val (SEQ ID NO: 1).